(S)-Gossypol (acetic acid)|cas 1189561-66-7|DC Chemicals

Cas No.:	1189561-66-7
Synonyms:	(S)-(+)-Gossypol acetic acid
SMILES:	OC1=C2C(C=O)=C(O)C(O)=C(C(C)C)C2=CC(C)=[C@@]1[C@@]3=C(C)C=C4C(C(C)C)=C(O)C(O)=C(C=O)C4=C3O.CC(O)=O
Formula:	C₃₂H₃₄O₁₀
M.Wt:	578.6064
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

(S)-Gossypol acetic acid is a inhibitor of Bcl-2, potently induce cell death in Jurkat cells overexpressing Bcl-2 (IC50, 18.1μM) or Bcl-xL (IC50, 22.9μM). in vitro: Gossypol-acetic acid significantly inhibited the proliferation of RAW264.7 cells in a dose-dependent manner, and caused obvious cell apoptosis and a loss of ΔΨm in RAW264.7 cells. Gossypol-acetic acid-induced cell apoptosis was markedly inhibited by caspase inhibitors. gossypol acetate resulted in a dose- and time-dependent inhibition of multiple myeloma cell proliferation, with an IC50 value to both U266 and Wus1 cells at 2.4, 2.2 μM at 48 h after treatment. Gossypol acetate effectively induced the apoptosis of multiple myeloma cells. Colorimetric assays showed activation of both caspase-3 and caspase-9. Bcl-2 and Bcl-xl expression was decreased by 86.5% and 35.9%, respectively, after treatment with gossypol acetate at 25 μM for 24 h . Gossypol-acetic acid (5-40 μM) inhibited the growth of MEC-1 cells in a dose- and time-dependent manner. Gossypol-acetic acid inhibits the proliferation of MEC-1, and DSB maybe one of the mechanisms of inhibitory effect of Gossypol-acetic acid on the growth of tumor cells. in vivo: A growth inhibition (T/C) of 30.9% (gossypol acetate 40 mg/kg) was obtained in Balb/C mice bearing Wus1 cells. In addition, there was no body weight loss for the treated group in comparison with the vehicle mice. Male rats were treated with gossypol acetic acid, GSH-Px specific activity increased in gossypol acetic acid group. gossypol acetic acid induce significant increases in the hepatic NEFA with remarkable decrease in the total saturated fatty acids with a significant increase of PUFA. Gossypol-acetic acid has selective action on the sperm membrane of the rats, it inhibited sperm Ca2+ influx in a dose-dependent manner, and exerts no effect on the high K+ induced contraction of smooth muscle of isolated rat.

MSDS

COA

LOT NO.	DOWNLOAD

2018-0101

Cat. No.	Product name	Field of application
DC46583	BM-1244	BM-1244 is a potent Bcl-xL/Bcl-2 inhibitor with Kis of 134 and 450 nM for Bcl- xL and Bcl-2, respectively. BM-1244 inhibits senescent fibroblasts (SnCs) with an EC50 of 5 nM. (From patent WO2019033119A1).
DC46458	Mcl-1 inhibitor 6	Mcl-1 inhibitor 6 is an orally active, selective myeloid cell leukemia 1 (Mcl-1) protein inhibitor with a Kd of 0.23 nM and a Ki of 0.02 μM. Mcl-1 inhibitor 6 possesses superior selectivity over other Bcl-2 family members (Bcl-2, Bcl2A1, Bcl-xL, and Bcl-w, Kd>10 μM). Mcl-1 inhibitor 6 is a potent antitumor agent.
DC46388	F1324	F1324 is a potent, high affinity peptidic inhibitor of B cell lymphoma 6 (BCL6) with an IC50 of 1 nM. F1324 exhibits binding t1/2 value of 441 s and has strong inhibition activity against BCL6 PPI.
DC46248	PUMA BH3 TFA	PUMA BH3 (TFA) is a p53 upregulated modulator of apoptosis (PUMA) BH3 domain peptide, acts as a direct activator of Bak, with a Kd of 26 nM.
DC45902	S65487 sulfate	S65487 (VOB560) sulfate is a potent and selective Bcl-2 inhibitor. S65487 sulfate is also active on BCL-2 mutations, such as G101V and D103Y. S65487 sulfate has poor affinity with MCL-1, BFL-1 and BCL-XL. S65487 sulfate induces apoptosis and has anticaner activities.
DC45547	MSN-50	MSN-50 is a Bax and Bak oligomerization inhibitor, efficiently inhibiting liposome permeabilization, preventing genotoxic cell death and promoting neuroprotection.
DC44826	S65487	S65487 (VOB560) is a potent and selective Bcl-2 inhibitor. S65487 has poor affinity with MCL-1, BFL-1 and BCL-XL. S65487 has anticaner activities.
DC44825	PUMA BH3	PUMA BH3 is a p53 upregulated modulator of apoptosis (PUMA) BH3 domain peptide, acts as a direct activator of Bak, with a Kd of 26 nM.
DC41980	BAD (103-127) (human)	BAD (103-127) (human), the 25-mer Bad peptide, is derived from the BH3 domain of BAD, can antagonize the function of Bcl-xL. BAD (103-127) (human) is reported to have almost 800-fold higher affinity for Bcl-XL than the 16-mer peptide.
DC41014	BCL6-IN-5	BCL6-IN-5 is a potent BCL6 inhibitor exacted from patent WO2018215801A1, example 1n, has a pIC50 of 5.82.